Vaccinex Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Vaccinex
VCNX Stock  USD 3.69  0.13  3.65%   
Vaccinex financial statements provide useful quarterly and yearly information to potential Vaccinex investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vaccinex financial statements helps investors assess Vaccinex's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vaccinex's valuation are summarized below:
Gross Profit
-13.7 M
Market Capitalization
9.9 M
Enterprise Value Revenue
22.0407
Revenue
356 K
Earnings Share
7.42
We have found one hundred twenty available fundamental trend indicators for Vaccinex, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vaccinex current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 4.1 M in 2024. Enterprise Value is likely to drop to about 2.9 M in 2024

Vaccinex Total Revenue

450,038

Check Vaccinex financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaccinex's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 19.7 K or Depreciation And Amortization of 181 K, as well as many indicators such as Price To Sales Ratio of 7.19, Dividend Yield of 0.0 or Days Sales Outstanding of 451. Vaccinex financial statements analysis is a perfect complement when working with Vaccinex Valuation or Volatility modules.
  
Check out the analysis of Vaccinex Correlation against competitors.
For more information on how to buy Vaccinex Stock please use our How to Invest in Vaccinex guide.

Vaccinex Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets6.8 M3.6 M6.1 M
Slightly volatile
Short and Long Term Debt Total234.7 K247 K2.6 M
Pretty Stable
Other Current Liabilities1.9 M3.4 M2.2 M
Very volatile
Total Current Liabilities4.6 M5.9 M5.2 M
Pretty Stable
Other Liabilities425.2 K332.1 K522 K
Slightly volatile
Property Plant And Equipment Net416.4 K282 K597.4 K
Slightly volatile
Accounts Payable1.8 M2 M2.3 M
Slightly volatile
Cash1.5 M1.5 M3.5 M
Slightly volatile
Non Current Assets Total416.4 K282 K597.4 K
Slightly volatile
Long Term Debt24.7 K26 K920 K
Slightly volatile
Cash And Short Term Investments1.5 M1.5 M4.5 M
Slightly volatile
Common Stock Shares Outstanding486.8 K463.6 K111.9 K
Slightly volatile
Long Term Debt Total2.1 M3.2 M2 M
Slightly volatile
Liabilities And Stockholders Equity6.8 M3.6 M6.1 M
Slightly volatile
Capital Surpluse148.1 M255.8 M128.8 M
Slightly volatile
Other Current Assets946.5 K853 K660.8 K
Slightly volatile
Other Stockholder Equity244.4 M337.6 M158.7 M
Slightly volatile
Total Liabilities5.3 M5.9 M6.3 M
Very volatile
Property Plant And Equipment Gross7.7 M7.4 M2.5 M
Slightly volatile
Short and Long Term Debt71.2 K75 K2.3 M
Pretty Stable
Preferred Stock Total Equity127 M137.3 M117.4 M
Slightly volatile
Total Current Assets6.4 M3.3 M5.5 M
Slightly volatile
Non Current Liabilities Other118.5 M128.5 M109.6 M
Slightly volatile
Short Term Debt348.6 K367 K2.4 M
Pretty Stable
Common Stock6 K5.8 K2.2 K
Slightly volatile
Property Plant Equipment451.1 K394.2 K603.1 K
Slightly volatile
Current Deferred Revenue53.9 K56.7 K187.3 K
Slightly volatile
Common Stock Total Equity1.8 K3.5 K1.6 K
Slightly volatile
Inventory0.80.90.98
Slightly volatile
Other Assets0.80.90.98
Slightly volatile

Vaccinex Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income19.7 K20.7 K3.1 M
Slightly volatile
Depreciation And Amortization181 K119 K203.9 K
Pretty Stable
Selling General Administrative6.5 M6.9 M5.3 M
Slightly volatile
Total Revenue450 K570 K374.6 K
Pretty Stable
Other Operating Expenses19.8 M23.5 M22.7 M
Slightly volatile
Research Development15 M16.6 M17.4 M
Pretty Stable
Cost Of Revenue17.4 M16.6 M2.4 M
Slightly volatile
Total Operating Expenses27 M23.5 M23 M
Slightly volatile
Reconciled Depreciation171.2 K137 K207.4 K
Pretty Stable
Selling And Marketing Expenses144.8 K162.9 K177.4 K
Slightly volatile

Vaccinex Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock44.8 M42.7 M23.7 M
Slightly volatile
Stock Based Compensation463.4 K474 K309.6 K
Slightly volatile
Begin Period Cash Flow6.3 M6.4 M5.8 M
Pretty Stable
Depreciation165.8 K119 K192.8 K
Very volatile
Capital Expenditures63.6 K67 K432.2 K
Slightly volatile
Total Cash From Financing Activities18.5 M12.4 M20.1 M
Pretty Stable
End Period Cash Flow1.5 M1.5 M3.5 M
Slightly volatile
Issuance Of Capital Stock18.7 M11.3 M30.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.197.573224
Very volatile
Days Sales Outstanding451615384
Slightly volatile
Stock Based Compensation To Revenue0.790.83161.9965
Slightly volatile
Capex To Depreciation0.530.5632.3725
Slightly volatile
EV To Sales5.055.3133215
Pretty Stable
Days Of Inventory On Hand0.00150.00160.014
Pretty Stable
Payables Turnover0.140.160.101
Slightly volatile
Sales General And Administrative To Revenue11.4712.071927.1802
Pretty Stable
Average Inventory0.40.450.49
Slightly volatile
Research And Ddevelopement To Revenue27.6229.077284.3627
Pretty Stable
Capex To Revenue0.110.11751.7233
Slightly volatile
Cash Per Share3.153.3107110
Very volatile
Days Payables Outstanding2.3 K2.4 K43.6 K
Pretty Stable
Income Quality1.140.8511.1958
Slightly volatile
Net Debt To EBITDA0.120.06520.1124
Slightly volatile
Current Ratio0.540.56611.1593
Slightly volatile
Receivables Turnover1.10.59311.7939
Slightly volatile
Graham Number66.4969.98811.3 K
Slightly volatile
Capex Per Share0.140.144515.1483
Slightly volatile
Revenue Per Share1.171.22948.9715
Slightly volatile
Interest Debt Per Share0.510.534997.457
Slightly volatile
Debt To Assets0.06460.0680.3747
Pretty Stable
Days Of Payables Outstanding2.3 K2.4 K43.6 K
Pretty Stable
Ebt Per Ebit0.750.88490.8285
Slightly volatile
Quick Ratio0.540.56611.1593
Slightly volatile
Net Income Per E B T0.810.90.9835
Slightly volatile
Cash Ratio0.250.25950.8337
Slightly volatile
Days Of Inventory Outstanding0.00150.00160.014
Pretty Stable
Days Of Sales Outstanding451615384
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00391.0285
Pretty Stable
Fixed Asset Turnover2.122.02130.785
Slightly volatile
Debt Ratio0.06460.0680.3747
Pretty Stable
Price Sales Ratio7.197.573224
Very volatile
Asset Turnover0.160.1570.0911
Pretty Stable
Operating Cycle444575380
Slightly volatile

Vaccinex Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.1 M4.3 M46.1 M
Slightly volatile
Enterprise Value2.9 M3 M44.1 M
Slightly volatile

Vaccinex Fundamental Market Drivers

Cash And Short Term Investments1.5 M

Vaccinex Upcoming Events

1st of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Vaccinex Financial Statements

Vaccinex investors use historical fundamental indicators, such as Vaccinex's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaccinex. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue56.7 K53.9 K
Total Revenue570 K450 K
Cost Of Revenue16.6 M17.4 M
Stock Based Compensation To Revenue 0.83  0.79 
Sales General And Administrative To Revenue 12.07  11.47 
Research And Ddevelopement To Revenue 29.08  27.62 
Capex To Revenue 0.12  0.11 
Revenue Per Share 1.23  1.17 
Ebit Per Revenue(40.15)(42.16)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Vaccinex Stock Analysis

When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY